Can blood flow assays help to identify clinically relevant differences in von Willebrand factor functionality in von Willebrand disease types 1-3? [2]

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 3, 2008, Pages 545-546

  Favaloro, Emmanuel J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 8C; COLLAGEN; GLYCOPROTEIN IB; VON WILLEBRAND FACTOR;

ASSAY; BLOOD FLOW; DISEASE CLASSIFICATION; GENE MUTATION; HEMATOCRIT; HUMAN; LETTER; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; HUMANS; MODELS, BIOLOGICAL; MUTATION; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC; REGIONAL BLOOD FLOW; REPRODUCIBILITY OF RESULTS; STRESS, MECHANICAL; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 39549108661     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02877.x     Document Type: Letter

References (7)

1. Zwaginga JJ, Sakariassen KS, King MR, Diacovo TG, Grabowski EF, Nash G, Hoylaerts M, Heemskerk JWM, the Biorheology Subcommittee of the SSC of the ISTH. Can blood flow assays help to identify clinically relevant differences in von Willebrand factor functionality in von Willebrand disease types 1-3? J Thromb Haemost 2007; 5: 2547-9.
2. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-5.
3. Sadler JE, Budde U, Eikenboom JCJ, Favaloro EJ, Hill FGH, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, et al. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on vonWillebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
4. Ribba AS, Loisel I, Lavergne JM, Juhan-Vague I, Obert B, Cherel G, Meyer D,Girma JP. Ser968Thr mutation within the A3 domain of von Ser968Thr mutation within the A3 domain of von binding of VWF to collagen. Thromb Haemost 2001; 86: 848-54.
5. Favaloro EJ. Laboratory identification of von Willebrand Disease: technical and scientific perspectives. Semin Thromb Hemost 2006; 32: 456-71.
6. Favaloro EJ. An update on the von Willebrand factor collagen binding (VWF:CB) assay: 21 years of age and beyond adolescence, but not yet a mature adult. Semin Thromb Hemost 2007; 33: 727-44.
7. Favaloro EJ. The utility of the PFA-100 in identification of von Willebrand Disease: A concise review. Semin Thromb Hemost 2006; 32: 537-45.